


In response to a growing demand for flexibility and convenience.



Genotropin™ (somatropin (rbe)) is available in a 12 IU Multidose vial. Once reconstituted Genotropin 12 IU Multidose can be stored in a refrigerator for up to two weeks. This makes the use of individually titrated dosage regimens a practical proposition and reduces the time spent preparing injections.

The combination of authentic sequence growth hormone and multidose presentation makes the introduction of Genotropin 12 IU Multidose a significant development for patients requiring growth hormone therapy.

Genotropin™ 12 IU Multidose somatropin (rbe)

PRESCRIBING INFORMATION ▼ **Presentation** A vial of sterile lyophilised powder containing 12 IU somatropin (rbe) supplied with 3 ml of Water for Injections with 0.25% m-cresol for reconstitution. **Indications** The treatment of short stature caused by decreased or absent secretion of pituitary growth hormone. **Reconstitution** Add 3 ml of Water for Injections with 0.25% m-cresol to the lyophilised powder in the vial. Dissolve the drug gently without shaking vigorously. **Dosage and Administration** Administer by subcutaneous or intramuscular injection. Generally a dose of 0.5 - 0.7 IU/kg body weight per week is recommended divided into six or seven subcutaneous injections. Alternatively two to three intramuscular injections can be given. **Contra-Indications** Only patients with unfused epiphyses should be treated. **Precautions** Patients with diabetes mellitus may require adjustment of their antidiabetic therapy. Patients treated with Genotropin should be regularly assessed by a child growth specialist. If given subcutaneously, the injection site should be rotated to prevent lipoatrophy. **Pregnancy and Lactation** In the event of pregnancy occurring during Genotropin therapy, treatment should be discontinued. No information is available as to whether peptide hormones pass into breast milk. **Side-Effects** A few children developed transient local skin reactions during clinical trials. Some patients develop antibodies to growth hormone although the frequency with Genotropin has been low in clinical trials. **Pharmaceutical Precautions** Store between 2-8°C and protect from light. Reconstituted Genotropin 12 IU Multidose may be stored for up to 2 weeks in the refrigerator. **Legal Category** POM. **Package Quantities** Combined pack containing one vial of somatropin (rbe) 12 IU and one vial of Water for Injections with 0.25% m-cresol. **Product Licence Numbers** Genotropin 12 IU Multidose PL 0022/0079. Water for Injections with 0.25% m-cresol PL 0022/0081. **Price** NHS Price £91.50. **Product Licence Holder** KabiVitrum Ltd, KabiVitrum House, Riverside Way, Uxbridge, Middlesex UB8 2YF. Further information is available on request from the product licence holder.

KABI

AZACTAM

aztreonam

Confidence in paediatric gram-negative infections



AZACTAM

ABBREVIATED PRESCRIBING INFORMATION AZACTAM

Presentation Vials containing 500mg, 1g, 2g aztreonam. Infusion bottle containing 2g aztreonam. All with L-arginine.
Indications for the treatment of the following infections caused by susceptible aerobic Gram-negative micro-organisms: Urinary tract infections, gonorrhoea, lower respiratory tract infections (including pneumonia, bronchitis, lung infections in patients with cystic fibrosis), septicæmia, meningitis caused by Haemophilus influenzae or Neisseria meningitidis, bone and joint infections, skin and soft-tissue infections, intra-abdominal infections and gynaecological infections.
Dosage and administration Adults: 1g-6g daily in divided doses depending on site and severity of infection. The usual dose is 3-4g daily. In serious infections a dose of 6-8g daily is recommended. In cystic fibrosis 2g 6-8 hourly IV. Gonorrhoea/cystitis 1g im, single dose. Children: patients older than 1 week 30mg/kg/dose every 6-8 hours. For severe infections in patients 2 years of age or older, 50mg/kg/dose every 6 or 8 hours is recommended. Total daily dose should not exceed

8g. Dosage information not available for newborns less than 1 week old. Azactam can be given intravenously or intramuscularly. Intravenous injection or infusion is recommended for doses greater than 1g. Adjust dosage in renal impairment. (See Data Sheet.)
Contra-indications Patients with a known hypersensitivity to Azactam.
Pregnancy
Precautions Initial concurrent therapy with other antibiotics is recommended for infections which may be due to non-susceptible organisms. (See Data Sheet.) Lactating mothers should refrain from breast feeding. Therapy with Azactam may result in superinfections which may require additional therapy. Impaired renal/hepatic function. Caution should be exercised in patients with beta-lactam hypersensitivity. Prothrombin times should be monitored in patients with concomitant anticoagulant therapy.
Side effects Aztreonam is generally well tolerated. Side-effects include rash, local reactions at the injection site, diarrhoea, nausea, vomiting.

(See Data Sheet.)
Legal category POM.
Product Licence No./Cost Azactam injection 500mg vial PL0034/0250 £4.45, 1g vial PL0034/0251 £8.95, 2g vial PL0034/0252 £17.90, 2g infusion bottle PL0034/0255 £17.90.
Product Licence Holder E.R. Squibb and Sons Ltd, Squibb House, Hounslow, Middlesex TW3 3JA.
Date of preparation May 1989.



Investing in Britain

E.R. Squibb & Sons Limited, Squibb House, 141-149 Staines Road, Hounslow, Middlesex TW3 3JA.



If in doubt, recommend Farley's OsterSoy.

If a baby's intolerant of standard cows' milk formulas, he'll be downright furious if you don't recommend a good alternative.

Unlike some soya protein formulas, Farley's OsterSoy is sucrose free. And it's the only brand you can prescribe for babies with cows' milk protein, lactose and sucrose intolerance.

Farley's OsterSoy is also one of the few soya

brands to meet DHSS and CODEX guidelines on protein and iron for standard milk formulas.

There's good news for vegetarians and vegans too. Farley's OsterSoy is the only soya formula that is completely free from all animal products.


So if there is a problem with cows' milk, the answer is Farley's OsterSoy. No question about it.



SO FA LEYS O GOO

PROGRESS

In The Management Of Cystic Fibrosis



creon[®] 
pancreatin

RIGHT ON TARGET – RIGHT FROM THE START

Prescribing Information – Presentation: Brown-yellow capsules containing enteric coated granules of pancreatin equivalent to: 9,000 BP units of amylase, 8,000 BP units of lipase, 210 BP units of protease. Available in packs of 100. Basic NHS price £13.33. **Indication:** Pancreatic exocrine insufficiency. **Dosage and administration:** Adults and children: Initially one or two capsules with meals, then adjust according to response. The capsules can be swallowed whole, or for ease of administration they may be opened and the granules taken with fluid or soft food, but without chewing. If the granules are mixed with food, it is important that they are taken immediately, otherwise dissolution of the enteric coating may result. **Contra-indications,**

Warnings, etc: Contra-indications: Substitution with pancreatic enzymes is contra-indicated in the early stages of acute pancreatitis. **Warnings:** Use in pregnancy: There is inadequate evidence of safety in use during pregnancy. The product is of porcine origin. Rarely cases of hyper-uricosuria and hyper-uricaemia have been reported with high doses of pancreatin. Overdosage could precipitate meconium ileus equivalent. Perianal irritation could occur, and, rarely, inflammation when large doses are used. **Product Licence Number:** 5727/0001. **Name and address of Licence Holder:** Kali Chemie Pharma GmbH, Postfach 220, D-3000, Hannover 1, West Germany.

duphar

Further information is available from:
Duphar Laboratories Limited, Gaters Hill, West End, Southampton SO3 3JD. Tel: 0703 472281.


CRA/CF/1/89

Air-Shields Vickers

The Resuscitaire 165 provides all the basic facilities necessary to help babies born with breathing difficulties survive the immediate post-natal period. Its compact, self contained construction makes it easily mobile for use in the ward or theatre. It's comprehensive facilities makes the Resuscitaire 165 a totally practical and comprehensive resuscitation system.

The Neocrib is an alternative clinical approach to the incubator for the intensive care of the sick and preterm neonate. It provides continuous unrestricted access, clear visibility and a safe controlled thermal neutral environment. Built in features include sophisticated temperature control, large clear digital displays, fold down side walls, continuously variable bed tilt, two monitor shelves and IV pole and X-ray cassette tray.

The Neocare Mk2 incubator available in both air and baby modes, provides the safe, warm environment, essential in caring for the critical neonate. In addition to the standard bi-directional air flow system, independent temperature control and measurement, and comprehensive alarm system there is a wide range of optional accessories available which can tailor the Neocare for handling any situation in neonatal care.



Providing
Special Care
for Neonates.



S&W Vickers

S&W Vickers Ltd, Ruxley Corner, Sidcup, Kent DA14 5BL

Telephone: 01-309 0433 Telex: 896328 Fax: 01-309 0919



VIRAZIDTM

Ribavirin

Effective therapy
for bronchiolitis
due to RSV



Now you can treat the infection
Not just the symptoms

Prescribing Information ▼

Indications

Virazid is indicated in the treatment of infants and children with severe respiratory syncytial virus bronchiolitis.

Dosage

Treatment is carried out using a small particle aerosol generator (SPAG) for 12-18 hours per day for at least 3 and no more than 7 days. The concentration of ribavirin in the reservoir is 20mg/ml in the SPAG unit and the average concentration for a 7 hour period is 0.19mg/l of air.

Presentation

Virazid is a sterile lyophilised powder of ribavirin to be reconstituted for aerosol administration. Each 100ml glass vial contains 6g of ribavirin and, when reconstituted to the correct volume of 300ml with Water for Injections BP, will

contain 20mg/ml ribavirin at a pH of approximately 5.5.

Contra-Indications

Ribavirin is contra-indicated in females who are or may become pregnant and it should be noted that ribavirin can be detected in human blood even four weeks after oral administration has ceased.

Precautions

In infants requiring assisted ventilation, Virazid should only be used when there is constant monitoring of both patients and equipment.

Side Effects

Several serious adverse events occurred in severely ill infants with life-threatening underlying disease many of whom required

assisted ventilation. These events included worsening of respiratory status, bacterial pneumonia and pneumothorax. The role of ribavirin aerosol in these events has not been determined.

Anaemia has been reported with oral and intravenous administration but no such incidents have been reported with aerosol administration. Reticulocytosis has been reported with aerosol use.

Warnings

Precipitation of the drug in respiratory equipment and consequent accumulation of fluid in the tubing has caused difficulties for patients requiring assisted ventilation.

In infants requiring assisted ventilation Virazid should only be used when there is constant monitoring of both patients and equipment.

Directions for use during assisted ventilation are given in the SPAG manual which should be read carefully before such administration.

Full prescribing information is available upon request.

▼ Special reporting to the CSM required.

Basic NHS Price: 1 x 6g vial £195.

Product Licence Number: 4657/0004

Product Licence Holder: Viratek Inc. USA

Supplied By: Britannia Pharmaceuticals Ltd
Forum House
41-51 Brighton Road
Redhill, Surrey,
RH1 6YS

Annotation

Growth hormone therapy and leukaemia
N. Stahnke, H. J. Zeisel 591

Endocrinology

Seasonal variation of haemoglobin A1 in children with insulin-dependent diabetes mellitus
F. R. J. Hinde, P. J. Standen, N. P. Mann, D. I. Johnston 597

Precocious pseudopuberty associated with multiple ovarian follicular cysts and low plasma oestradiol concentrations
G. Sinnecker, R. P. Willig, N. Stahnke, W. Braendle 600

Graves disease presenting as painful thyroiditis
C. Alves, M. S. Eidson, M. Zakarija, J. M. McKenzie 603

Gastroenterology/Hepatology

25 Hydroxyvitamin D and vitamin E absorption in healthy children and children with chronic intrahepatic cholestasis
S. Issa, H. W. Rothauwe, W. Burmeister 605

Unchanging clinical picture of coeliac disease presentation in Campania, Italy
L. Greco, A. E. Tozzi, M. Mayer, M. Girmaldi, G. Silano, S. Auricchio 610

Growth/Development

Gas exchange during exercise in obese children
S. Zanconato, E. Baraldi, P. Santuz, F. Rigon, L. Vido, L. Da Dalt, F. Zacchello 614

Hematology/Oncology

Mild course of mumps in patients with acute lymphoblastic leukaemia
A. W. de Boer, G. A. M. de Vaan 618

Structural alteration of the insulin-like growth factor II-gene in Wilms tumour
J. C. Irminger, E. J. Schoenle, J. Briner, R. E. Humbel 620

Membranous nephropathy associated with ovarian tumour in a young girl: recovery after removal
P. Beauvais, G. Vaudour, L. Boccon Gibod, M. Levy 624

Immunology/Allergology

Systemic lupus erythematosus of childhood onset: correlation between T cells expressing early and late activation antigens and disease activity
T. Hara, S. Hisano, Y. Mizuno, K. Hatae, M. Kurokawa, K. Ueda, T. Sakaguchi, M. Umene, M. Mizukoshi 626

Administration of recombinant IL-2 augments the level of serum IgM in an IL-2 deficient patient
S. Doi, O. Saiki, T. Hara, T. Sugita, K. Ha-Kawa, T. Tanaka, H. Hara, S. Negoro, H. Yabuuchi, S. Kishimoto 630

Infectious diseases

A trial of RIT-4237 rotavirus vaccine in 1-month-old infants
I. D. Mutz, F. Krainer, J. Deutsch, Ch. Kunz, D. E. Teuwen 634

Familial Mediterranean fever (recurrent hereditary polyserositis) in children: analysis of 88 cases
H. A. Majeed, M. Barakat 636

Coxsackie B3 virus encephalitis in a patient with agammaglobulinaemia
N. T. Hertel, F. K. Pedersen, C. Heilmann 642

Tumour necrosis factor in neonatal listeriosis: a case report
E. Girardin, M. Berner, G. E. Grau, J.-M. Dayer, P. Roux-Lombard, S. Suter 644

Recurrent meningitis: a case report
M. Ceccarelli, M. Balestri, C. Fontani, L. Lupetti, C. Ughi 646

Haemolytic-uraemic syndrome associated with *Streptococcus pneumoniae* meningitis
A. Martinot, V. Hue, F. Leclerc, M. Chenaud 648

Hypercalcaemia in a child with miliary tuberculosis
J. Gerritsen, K. Knol 650

Medical genetics

Robinow syndrome with parental consanguinity
D. Glaser, J. Herbst, K. Roggenkamp, W. Tünte, W. Lenz 652

Metabolic diseases

Oral zinc sulphate as primary therapeutic intervention in a child with Wilson disease
R. Milanino, M. Marrella, U. Moretti, G. P. Velo, A. Deganello, G. Ribezzo, L. Tatò 654

Fatal neonatal cardiomyopathy associated with cataract and mitochondrial myopathy
J. A. M. Smeitink, R. C. A. Sengers, J. M. F. Trijbels, W. Ruitenbeek, O. Daniëls, A. M. Stadhouders, M. J. H. Kock-Jansen 656

Neonatology

Abnormal blood flow patterns in renal arteries of small preterm infants with patent ductus arteriosus detected by Doppler ultrasonography
T. Bömelburg, G. Jorch 660

The use of a synthetic skin covering as a protective layer in the daily care of low birth weight infants
M. Barak, S. Hershkowitz, R. Rod, S. Dror 665

Neuropediatrics

A patient with infantile spasms and low homovanillic acid levels in cerebrospinal fluid: L-dopa dependent seizures?
H. Sugie, Y. Sugie, N. Kato, Y. Fukuyama 667

Nutrition

Effects of dietary long-chain polyunsaturated fatty acids on the essential fatty acid status of premature infants
B. Koletzko, E. Schmidt, H. J. Bremer, M. Haug, G. Harzer 669

Milk bolus obstruction secondary to the early introduction of premature baby milk formula: an old syndrome re-emerging in a new population
J. K. H. Wales, D. Milford, N. M. Okorie 676

Pharmacology

Concentrations of ceftazidime, tobramycin and ampicillin in the cerebrospinal fluid of newborn infants
I. Tessin, B. Trollfors, K. Thiringer, Z. Thörn, P. Larsson 679

Letters to the editors

Optic atrophy in aqueduct stenosis
K. Maruyama, O. Arisaka, T. Lee, K. Yabuta, K. Sato 682

Microalbuminuria and glycaemic control in diabetic children
F. Chiarelli, G. La Penna, G. Morgese 682

Reply
P. Mullis 683

Amplification of clone 8 as a prognostic indicator of neuroblastoma
A. Nakagawara, T. Tsuda, K. Higashi 684

Abstracts

The 12th Meeting of the European Society for Paediatric Haematology and Immunology (ESPHI) held in Paris, 19-21 July 1989 685

Indexed in *Current Contents*



Springer International

Subscription information

Volume 148 (8 issues) will appear in 1989. Information about obtaining back volumes and microform editions available upon request.

North America. Annual subscription rate: approx. US \$ 786.00 (single issue price approx. \$ 117.00), including carriage charges. Subscriptions are entered with prepayment only.

Orders should be addressed to:

Springer-Verlag New York Inc.
Service Center Secaucus
44 Hartz Way
Secaucus, NJ 07094, USA
Tel. (201) 348-4033
Telex 023 125 994

All other countries. Annual subscription rate: DM 1358.00 plus carriage charges; Federal Republic of Germany: DM 17.98 incl. value added tax; all other countries: DM 34.80 ex-

cept for the following countries to which SAL delivery (Surface Airmail Lifted) is mandatory: Japan DM 76.80, India DM 58.00, Australia/New Zealand DM 86.80. Airmail delivery to all other countries is available upon request. Volume price: DM 1358.00, single issue price: DM 203.70 plus carriage charges. Subscriptions can either be placed via a bookdealer or sent directly to:

Springer-Verlag
Heidelberger Platz 3, D-1000 Berlin 33
Tel. (0)30/8207-0, Telex 183319

MONATS KINDE SCHRIFT HEILKUNDE

137. Band Heft 8
August 1989

Organ der
Deutschen Gesellschaft
für Kinderheilkunde

Thema des Monats

Angeborene Knochen-
erkrankungen
Editorial 427

W. Lenz
Knochenkrankungen:
Überblick und Klassifikation
angeborener
Entwicklungsstörungen 428

Pädiatrie aktuell

Behandlung der zyklischen
Neutropenie mit
Granulozyten-CSF

Kontrollierte Studie zur
Frage, ob Diabetiker unter
Humaninsulin ihre Hypo-
glykämien schlechter
bemerkten als unter
Schweineinsulin

Wie verändert sich der
Pylorusmuskel nach der
Pyloromyotomie? 438

Indexed in Current Contents

Was hat das Kind?

Trainingsprogramm für die
Weiterbildung zum Kinder-
arzt 439

Klinik und Forschung

K. E. v. Mühlendahl
Nebenwirkungen und Kom-
plikationen der Masern-
Mumps-Impfung 440

J. Ryzko, R. S. Lorenc,
J. Socha, J. Lukaszkiwicz,
U. Preiß
Veränderungen des Vitamin
D-Stoffwechsels bei Kindern
nach partieller Darm-
resektion 447

Der interessante Fall

J. Reiß, M. Krawczak,
A. Gal, K. Zerres, R. Kaiser,
J. Weber
Risikoschwangerschaft einer
Anlageträgerin für cystische
Fibrose (Mukoviszidose) mit
einem neuen Partner 451

R. Ziegler, H. Schmidt,
A. C. Sewell, J. Weglage,
J. H. v. Lengerke, K. Ullrich
Aspartylglucosaminurie.
Klinische Beschreibung von
zwei deutschen
Patienten 454

A. Roy Choudhury,
E. Friederichs, Ch. P. Speer,
W. Schröter
Neonatale Alloimmunthrom-
bozytopenie — Einfluß
einer Kombinationstherapie
aus i.v.-Immunglobulingabe
und Transfusion
PIA¹-negativer maternalen
Thrombozyten 458

J. Krähe, U. Neudorf,
F. Hentrich
Das QT-Syndrom bei
Neugeborenen 463

A. A. Hartmann, G. Burg
Acne fulminans bei
Klinefelter-Syndrom unter
Testosteron. Eine Neben-
wirkung der Antihochwuchs-
therapie 466

H. E. Ulmer, W. Stolz,
G. Kühn, G. Meckersheimer
Ectopia cordis. Bericht über
einen pränatal diagnostizier-
ten Fall und eine kurze
Übersicht über die
Literatur 468

Wußten Sie schon?

Aus der Praxis —
für die Praxis

U. Dörffer
Anorexia hydrargyra. Kasui-
stik aus der Praxis 472

F. Daschner
Wider die Scharlach- und
Streptokokken-Abstrich-
neurose 472

Was hat das Kind?

Auflösung und Kommentar
des Trainingsprogramms für
die Weiterbildung zum
Kinderarzt 473

Neue Bücher 474

Tagesgeschichte,
Personalia 475

Tagungskalender 475

Abstracts der 85. Jahres-
tagung der Deutschen Gesell-
schaft für Kinderheilkunde,
17.—20. September 1989 in
Ulm 477



Springer-Verlag
Berlin Heidelberg New York
London Paris Tokyo Hong Kong

Annual subscription: DM 298,- plus postage

KANTHAL® BABY WARMER



A soft, warm watermattress is kept at an exact temperature (normally 37° C). It transfers its warmth very efficiently to the baby via direct contact.

Kanthal Baby Warmer will warm babies from 900 g and keep them warm in a safe and pleasant way.

For further information please contact.

KANTHAL Medical Heating

Äggelundavägen 2, S-175 62 Järfälla
Tel. + 46 8-761 75 80, Fax. + 46 8-761 05 52

UK Distributor Kanthal Medical Heating
Tel 0742-44 60 21



NATIONAL UNIVERSITY OF SINGAPORE DEPARTMENT OF PAEDIATRICS

Applications are invited for a visiting appointment as Teaching Fellow in the Department of Paediatrics.

Candidates should be competent general paediatricians with a subspecialty interest and possess an approved basic medical degree with relevant higher professional/academic qualifications. Preference will be given to those with proven research capability.

Gross annual emoluments range from S\$53,160 to S\$64,200. (STGE1-00=S\$3-10 approx.)

The commencing salary will depend on the candidate's qualifications and experience. In addition, under the Professional Fee Scheme (which is administered by the National University Hospital) the appointee will receive a Fixed Specialist Allowance (FSA), the annual rates for which is S\$6,000/9,000.

Leave and medical benefits will be provided. Depending on the type of contract offered, other benefits may include: provident fund benefits or an end-of-contract gratuity, a settling-in allowance of S\$1,000 or S\$2,000, subsidised housing at nominal rentals ranging from S\$100 to S\$216 p.m., education allowance for up to three children subject to a maximum of S\$10,000 per annum per child, passage assistance and baggage allowance for the transportation of personal effects to Singapore.

Application forms and further information on terms and conditions of service may be obtained from:

The Director
Personnel Department
National University of Singapore
10 Kent Ridge Crescent
Singapore 0511

NUS Overseas Office
Singapore High Commission in London
5 Chesham Street
London SW1
U.K.
Tel: (01) 235-4562

Enquiries may also be sent through BITNET to: PERSDEPT @ NUSVM, or through Telefax: (65) 7783948

PRESCRIBING INFORMATION

HUMAN VELOSULIN (Neutral Insulin Injection, human insulin (emp)). **HUMAN INSULATARD** (Isophane Insulin Injection (NPH), human insulin (emp)). **HUMAN MIXTARD 30/70** (Neutral Suspension comprising 30% Neutral Insulin Injection and 70% Isophane Insulin Injection (NPH), human insulin (emp)). **HUMAN INITARD 50/50** (Neutral Suspension comprising 50% Neutral Insulin Injection and 50% Isophane Insulin Injection (NPH), human insulin (emp)). **Presentation** HUMAN VELOSULIN, HUMAN INSULATARD, HUMAN MIXTARD 30/70 and HUMAN INITARD 50/50 are available in 10 ml. vials containing 100 iu/ml. To aid identification the metal sealing rings of the vials have tactile marks as follows: Human Velosulin - one mark; Human Insulatard - two marks; Human Mixtard 30/70 - three marks; Human Initard 50/50 - four marks. The vials are fitted with tamper-evident caps. **Uses** The treatment of insulin-requiring diabetes. **Dosage and Administration** The dosage of insulin is determined by the physician according to the needs of the patient. Human Velosulin may be given by s.c., i.m., or i.v. injection. Human Insulatard, Human Mixtard 30/70 and Human Initard 50/50 should be re-suspended by inverting the vial several times before being given by s.c. or i.m. injection (they must not be given intravenously). Intermixing does not affect the characteristics of any of these insulins. **Use in pregnancy** Insulin requirements usually fall during the first trimester and increase during the second and third trimesters. **Use in the elderly:** Insulin may have a more prolonged action due to reduced clearance rates. **Contra-indications warnings etc. Contra-indications:** Hypoglycaemia. **Precautions:** Patients transferring from other insulins may require a dosage adjustment. Concomitant therapy with thyroxine, corticosteroids, oral contraceptives, diuretics, beta blockers and M.A.O.I.s may affect insulin requirements. **Side and Adverse Effects:** Hypoglycaemia. Local reactions, lipodystrophy and hypersensitivity reactions are rarely reported with human insulins. **Pharmaceutical Precautions** be used. **Legal Category P. Package Quantities** 10 ml. glass vials. **Basic NHS Price** Human Insulatard 3132/0034; Human Mixtard 30/70 3132/0037; Human Initard 50/50 Insulatard 0003/0212; Human Mixtard 30/70 0003/0213; Human Initard 50/50 0003/0214. House, Garland Court, Garland Road, East Grinstead, West Sussex RH19 1DN. Foundation Ltd, Crewe Hall, Crewe, Cheshire CW1 1UB. Tel: Crewe (0270) 583151.



Store between 2-8°C, protected from sunlight. Insulin which has been frozen should not be used. **Product Licence Numbers** NORDISK-UK: Human Velosulin 3132/0031-3132/0040. THE WELLCOME FOUNDATION LTD: Human Velosulin 0003/0211; Human Insulatard 0003/0212; Human Mixtard 30/70 0003/0213; Human Initard 50/50 0003/0214. Further information is available on request from either: Nordisk-UK, Nordisk, Tel: East Grinstead (0342) 410373, or Wellcome Medical Division, The Wellcome Foundation Ltd, Beckenham, Kent BR3 1YQ. **Reference** I. Heine R.J. et al. Diabetologia, 1984; 27: 558-562. Registered Trade Mark



designed for each other...

HUMAN VELOSULIN®

Human neutral soluble insulin (emp)

HUMAN INSULATARD®

Human isophane (NPH) insulin (emp)

Quick and intermediate acting insulins developed to be compatible.

No interaction when mixed!

Predictable effect in individually titrated regimens.